Overview

Interleukin 3 (IL3) is a gene that encodes a protein that functions as a growth promoting cytokine. The protein maintains the proliferation of many hematopoietic cell types. The protein also plays a role in cell growth, differentiation, and apoptosis. Fusions, missense mutations, silent mutations, and frameshift insertions are observed in cancers such as intestinal cancer, skin cancer, and stomach cancer.

IL3 is altered in 0.13% of all cancers with follicular lymphoma, mature B-cell neoplasm, multiple myeloma, B-cell lymphoblastic leukemia/lymphoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma having the greatest prevalence of alterations [3].

The most common alterations in IL3 are IL3 D40E (0.85%), IL3 M68L (0.22%), IL3 R82S (0.39%), and IL3 T136_L137insP (0.85%) [3].

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.